Update on guidelines for management of hypercholesterolemia

@article{Mannu2012UpdateOG,
  title={Update on guidelines for management of hypercholesterolemia},
  author={G. Mannu and M. Zaman and Abhaya R. Gupta and H. Rehman and P. Myint},
  journal={Expert Review of Cardiovascular Therapy},
  year={2012},
  volume={10},
  pages={1239 - 1249}
}
Coronary heart disease (CHD) is a leading cause of morbidity and mortality globally. Hypercholesterolemia is one of the major risk factors for CHD. With the increase in aging populations and progressively sedentary lifestyles, the global burden of CHD is likely to increase in the future despite better preventive strategies. It is vitally important to manage hypercholesterolemia effectively because it is a modifiable risk factor. At present, there are several guidelines with differences in… Expand
Patients with Small Abdominal Aortic Aneurysm are at Significant Risk of Cardiovascular Events and this Risk is not Addressed Sufficiently.
TLDR
It is suggested that patients with small AAA are at significant risk for developing CV events and this is not currently addressed, which is evident by the "high-risk" CV risk profiles of these patients despite being in AAA surveillance. Expand
Multi-Centre Study on Cardiovascular Risk Management on Patients Undergoing AAA Surveillance.
  • A. Saratzis, N. Dattani, +4 authors P. Stather
  • Medicine
  • European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
  • 2017
TLDR
Many patients with small AAA are not prescribed an antiplatelet/statin, and still smoke cigarettes, and therefore remain at high risk of cardiovascular morbidity and mortality and national guidance to ensure this high risk group of patients is adequately protected from poor cardiovascular outcomes is lacking. Expand
Rheumatic Mitral Valve Disease Is Associated With Worse Outcomes in Stroke: A Thailand National Database Study
TLDR
RMVD is associated with the development of cardiac arrest, shock, arrhythmias, respiratory failure, pneumonia, and sepsis after acute stroke. Expand
SCREENING OF THE POTENTIAL ANTIHYPERCHOLESTERMIC ACTIVITY OF SOME EGYPTIAN HERBS
TLDR
Garden nasturtium and onion extracts have dual effect in reducing blood cholesterol and keep the normal appearance of blood vessel. Expand
Intervention Associated Acute Kidney Injury and Long-Term Cardiovascular Outcomes
TLDR
Investigation in patients undergoing open (OAR) or endovascular (EVAR) abdominal aortic aneurysm repair found AKI is associated with long-term CV events after surgery orendovascular intervention, and this was confirmed in other CV-interventions. Expand
Raphanus sativus ameliorates atherogeneic lipid profiles in hypercholesterolemic rats and hypercholesterolemia-associated peroxidative liver damage
Objective: Raphanus sativus is a hugely used edible root vegetable. We investigated whether the feeding of the Raphanus sativus hot water extract (RSE) ameliorates atherogenic lipid profile andExpand
The Protective Effect of White and Red Radish as Hypoglycemic and Hypocholesterolemic Agents
Radish, Raphanus Sativus L. (family: Brassicaceae) has been recognized since ancient times, roots and leaves are used for cooking and treatment of a wide variety ailments. White radish leaves (WRL),Expand
IONTOPHORESIS OF FLUVASTATIN SODIUM: STUDY OF VARIOUS FACTOR AND IN- VITRO PERMEATION
Fluvastatin sodium (FVS) is the first fully synthetic 3hydroxy-3-methylglutaryl coenzyme (HMG-CoA) reductase inhibitors used for the treatment of hypercholesterolemia. It shows extensive first passExpand

References

SHOWING 1-10 OF 93 REFERENCES
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary
TLDR
This guideline reinforces the view that doctors should not focus solely on blood pressure but must also formally assess total risk of cardiovascular disease and use multifactorial interventions, including statins and aspirin, to reduce it. Expand
Secondary prevention of coronary heart disease: the role of fibric acids.
TLDR
Themisclassification of key variables reduces the significance of relations in longitudinal studies, and it may also affect clinical trials by allowing the inclusion of subjects with, for example, elevated triglyceride levels but a low risk of CHD, and the direct measurement of apoB may improve the selection of patients in clinical trials. Expand
Progressing from risk factors to omics.
  • P. Wilson
  • Medicine
  • Circulation. Cardiovascular genetics
  • 2008
TLDR
Progress has been made from traditional risk factor assessment to the present time that includes newer assessment methods such as genomics, metabolomics, and predictive medicine, emphasizing the progress made in research and care for clinical atherosclerotic disease. Expand
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
TLDR
Pravastatin did not reduce either all-cause mortality or CHD significantly when compared with usual care in older participants with well-controlled hypertension and moderately elevated LDL-C. Expand
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
TLDR
Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of my Cardiac Infarction. Expand
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
TLDR
These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians but also specialists from lipid clinics or metabolic units who are dealing with dyslipIDAemias that are more difficult to classify and treat. Expand
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
TLDR
Among people with diabetes the proportional effects of statin therapy were similar irrespective of whether there was a prior history of vascular disease and irrespective of other baseline characteristics and should be considered for all diabetic individuals who are at sufficiently high risk of vascular events. Expand
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
TLDR
Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of my Cardiac Infarction. Expand
Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
The National Institute for Health and Clinical Excellence (NICE) guideline, Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondaryExpand
[Detection, evaluation, and treatment of high blood cholesterol in adults].
TLDR
This report advocates more intensive treatment in order to reduce low-density lipoprotein (LDL) cholesterol in specific groups of individuals and recognizes as a secondary prevention concern a cluster of heart disease risk factors known as "the metabolic syndrome". Expand
...
1
2
3
4
5
...